115 results on '"YASUSHI RINO"'
Search Results
2. Non-invasive intraductal oncocytic papillary neoplasm forming a protruding lesion toward the duodenum from the accessory papilla: a case report
- Author
-
Shinnosuke Kawahara, Naoto Yamamoto, Kota Washimi, Rei Kanemoto, Daishi Takahashi, Yuto Kamioka, Itaru Hashimoto, Mariko Kamiya, Aya Kato, Yukio Maezawa, Keisuke Kazama, Masaaki Murakawa, Sho Sawazaki, Toru Aoyama, Hiroshi Tamagawa, Takashi Oshima, Norio Yukawa, Yasushi Rino, Tomoyuki Yokose, Aya Saito, and Soichiro Morinaga
- Subjects
Intraductal oncocytic papillary neoplasm ,Pancreas ,Accessory papilla ,Non-invasive ,Surgery ,RD1-811 - Abstract
Abstract Background Intraductal oncocytic papillary neoplasm (IOPN), previously classified as a subtype of intraductal papillary mucinous neoplasm (IPMN), has been described as an independent disease by the WHO since 2019. IOPN is a rare tumor, with few reported cases. Herein, we report a case of resected non-invasive IOPN that formed a lesion protruding toward the duodenum from the accessory papilla. Case presentation An 80-year-old woman was referred to our hospital because of a giant mass in the pancreatic head detected on abdominal contrast-enhanced computed tomography (CT) performed for a close examination of a mass in the right breast. CT revealed a 90-mm-sized tumor with a mixture of solid and cystic components, with contrast enhancement in the pancreatic head, and a dilated main pancreatic duct. Esophagogastroduodenoscopy revealed a semi-circumferential papillary tumor protruding toward the duodenal lumen, which did not protrude from the papilla of Vater. Transpapillary biopsy led to a preoperative diagnosis of IPMN with an associated invasive carcinoma. As there were no distant metastasis, open subtotal stomach-preserving pancreaticoduodenectomy was performed. Analysis of the surgical specimen and histopathological examination revealed that the tumor was an IOPN that protruded toward the duodenal mucosa from the accessory papilla while replacing the duodenal mucosa with no obvious stromal invasion. Conclusion IOPN is a rare and poorly recognized tumor with few reported cases. There have been no reports describing IOPN forming a protruding lesion toward the duodenum from the accessory papilla. Therefore, further accumulation of cases such as this one is important to advance the study of IOPN.
- Published
- 2024
- Full Text
- View/download PDF
3. Long‐term treatment outcomes in gastric cancer with oligometastasis
- Author
-
Kentaro Hara, Haruhiko Cho, Atsushi Onodera, Kazuya Endo, Yukio Maezawa, Toru Aoyama, Takanobu Yamada, Takashi Oshima, and Yasushi Rino
- Subjects
chemotherapy ,gastrectomy ,gastric cancer ,metastasectomy ,oligometastasis ,Surgery ,RD1-811 ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Aim While surgery is essential for curative treatment of gastric cancer with oligometastasis, its target, timing, and possibility of combination with other treatments are unclear. We herein investigated the clinical course and long‐term outcomes of gastric cancer with oligometastasis in the real world setting to determine the optimal therapeutic strategy. Methods The present study retrospectively analyzed 992 patients who received any treatment for metastatic or recurrent gastric adenocarcinoma at Tokyo Metropolitan Komagome Hospital between 2007 and 2019. Oligometastasis was defined as any one of the following: liver metastases (HEP)
- Published
- 2024
- Full Text
- View/download PDF
4. Surgical outcomes of a prospective, phase 2 trial of robotic surgery for resectable right‐sided colon cancer (the ROBOCOLO trial)
- Author
-
Masakatsu Numata, Jun Watanabe, Atsushi Ishibe, Mayumi Ozawa, Yusuke Suwa, Keisuke Kazama, Kazuya Nakagawa, Yosuke Atsumi, Yasushi Rino, Aya Saito, Chikara Kunisaki, and Itaru Endo
- Subjects
colon cancer ,complete mesocolic excision ,intracorporeal anastomosis ,right hemicolectomy ,robotic surgery ,Surgery ,RD1-811 ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Aim We evaluated the safety of robotic surgery for right‐sided colon cancer in Japan. Methods This was a prospective, open‐label, single‐arm phase II trial conducted at two institutions. Patients ≥20 years old with stage I–III right‐sided colon cancer and scheduled for radical resection with ≥D2 lymph node dissection were eligible. The criterion for surgeons was experience performing robot‐assisted rectal resection in ≥40 cases. The primary endpoint was the postoperative complication rate ≤30 days after surgery. Results From August 2021 to February 2023, 42 patients were enrolled; three were excluded, with 39 analyzed as the full analysis set. The median age was 72 years, and the median body mass index was 23.2. The tumor was located in the cecum in 13 cases (33.3%), ascending colon in 20 cases (51.3%), and transverse colon in six cases (15.4%). Ileocolic resection was performed in 17 cases (43.5%) and right hemicolectomy in 22 cases (56.5%), both with D3 lymph node dissection. The median console time was 109 min, and the operative time was 170 min. The mean blood loss was 7.7 mL. Intracorporeal anastomosis was performed in 28 patients (71.8%). There were no conversions and no intraoperative adverse events. The median postoperative stay was 5 days. Postoperative complications occurred in four patients (10.2%; paralytic ileus [n = 3] and pneumonia [n = 1]). All postoperative complications were grade 1 or 2, with no mortalities noted. R0 resection was achieved in all patients. Conclusions This study demonstrated the safety and feasibility of robotic surgery for right‐sided colon cancer.
- Published
- 2024
- Full Text
- View/download PDF
5. Long‐term changes in psoas muscle mass after lobectomy and segmentectomy for early‐stage lung cancer
- Author
-
Tetsuya Isaka, Hiroyuki Ito, Tomoyuki Yokose, Haruhiro Saito, Hiroto Narimatsu, Hiroyuki Adachi, Jun Miura, Kotaro Murakami, Noritake Kikunishi, Naoko Shigeta, and Yasushi Rino
- Subjects
Less invasive ,Lobectomy ,Psoas muscle mass ,Psoas muscle area ,Sarcopenia ,Segmentectomy ,Diseases of the musculoskeletal system ,RC925-935 ,Human anatomy ,QM1-695 - Abstract
Abstract Background Segmentectomy is considered a less invasive procedure than lobectomy for patients with non‐small cell lung cancer (NSCLC); however, little is known about the physiological mechanism underlying the lower invasiveness of segmentectomy. This study is aimed to compare the differences in the long‐term changes in the psoas muscle mass after segmentectomy and lobectomy in patients with NSCLC. Methods Overall 315 recurrence‐free patients who underwent segmentectomy (n = 93) or lobectomy (n = 222) for clinical stage 0‐I NSCLC between January 2016 and December 2018 and underwent computed tomography during the entire period of 6 months ≤ postoperative year (POY) 0.5
- Published
- 2023
- Full Text
- View/download PDF
6. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection
- Author
-
Masaaki Murakawa, Shinnosuke Kawahara, Daishi Takahashi, Yuto Kamioka, Naoto Yamamoto, Satoshi Kobayashi, Makoto Ueno, Manabu Morimoto, Sho Sawazaki, Hiroshi Tamagawa, Takashi Ohshima, Norio Yukawa, Yasushi Rino, and Soichiro Morinaga
- Subjects
Pancreatic ductal adenocarcinoma ,Early recurrence ,Risk factors ,Neoadjuvant therapy ,Surgery ,RD1-811 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, and surgical resection is the only potentially curative approach. However, the rate of recurrence remains high, particularly within the first 6 months, and is associated with a poor prognosis. The present study evaluated the clinical characteristics and risk factors for early recurrence in pancreatic ductal adenocarcinoma (PDAC) patients who underwent curative resection, regardless of the use of neoadjuvant chemotherapy, to identify predictive factors associated with early recurrence and poor outcomes as well as to determine the optimal treatment strategy for patients at high risk of early recurrence after surgical resection. Methods Patients who underwent pancreatic resection for PDAC at our institution from 2013 to 2021 were included in this study. We investigated the clinicopathological features of patients in groups: those with recurrence within 6 months, recurrence between 6 and 12 months, and recurrence beyond 12 months or no recurrence. A logistic regression analysis identified covariates associated with early recurrence at 6 and 12 months. Results The study included 403 patients with a median follow-up of 25.7 months. Recurrence was observed in 279 patients, with 14.6% recurring within 6 months, 23.3% within 6–12 months, and 62% after 12 months or not at all. The preoperative CA19-9 level, modified Glasgow prognostic score (mGPS), and positive peritoneal cytology were significant risk factors for early recurrence within 6 months, while positive peritoneal cytology, lymph node metastasis, and the absence of adjuvant chemotherapy were significant risk factors for recurrence within 12 months. For patients who received preoperative chemotherapy or chemoradiotherapy, the preoperative CA19-9 level, mGPS, and positive peritoneal cytology were significant independent risk factors for early recurrence within 6 months, while positive peritoneal cytology, lymph node metastasis, and the absence of adjuvant chemotherapy were significant independent risk factors for recurrence within 12 months. The study concluded that the overall survival after surgical resection for potentially resectable PDAC worsened according to the number of risk factors present in the patient. Conclusions We clarified that preoperative CA19-9, positive peritoneal cytology, and the lack of adjuvant chemotherapy were consistent predictors for early recurrence within 6 and 12 months. In addition, an increased number of risk factors affecting the patient was associated with a poorer overall survival after potentially curable resection. Calculating the number of risk factors for early recurrence may be an essential predictive factor when considering treatment strategies.
- Published
- 2023
- Full Text
- View/download PDF
7. Left parathyroid carcinoma with secondary hyperparathyroidism: a case report
- Author
-
Ko Yokoyama, Nobuyasu Suganuma, and Yasushi Rino
- Subjects
Parathyroid carcinoma ,Hyperplasia ,Hypercalcemia ,Hyperparathyroidism ,Parathyroid hormone ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Abstract Background Parathyroid carcinoma is a rare disease with a frequency of 0.005% of all malignancies [1, 2]. Various aspects of its pathogenesis, diagnosis, and treatment remain poorly understood. Furthermore, cases with secondary hyperparathyroidism are fewer. In this case report, we describe a case of left parathyroid carcinoma with secondary hyperparathyroidism. Case presentation The patient was a 54-year-old woman who had been on hemodialysis since the age of 40 years. At 53 years of age, her calcium levels were high, and she was diagnosed with drug-resistant secondary hyperparathyroidism and was referred to our hospital for surgical treatment. Blood tests revealed calcium levels of 11.4 mg/dL and intact parathyroid hormone (PTH) levels of 1007 pg/mL. Neck ultrasonography revealed a 22-mm large round hypoechoic mass, partially indistinct margins, and D/W ratio > 1 at the left thyroid lobe. Computed tomography scans revealed a 20-mm nodule at the left thyroid lobe. No enlarged lymph nodes or distant metastases were noted. 99mTc-hexakis-2-methoxyisobutylisonitrile scintigraphy revealed an accumulation at the superior pole of the left thyroid lobe. Laryngeal endoscopy revealed paralysis of the left vocal cord, signifying recurrent nerve palsy due to parathyroid carcinoma. Based on these results, a diagnosis of secondary hyperparathyroidism and suspected left parathyroid carcinoma was made, and the patient underwent surgery. Pathology results revealed hyperplasia in the right upper and lower parathyroid glands. The left upper parathyroid gland showed capsular and venous invasion, and the diagnosis was left parathyroid carcinoma. At 4 months post-surgery, calcium levels improved to 8.7 mg/dL and intact PTH levels to 20 pg/mL, with no signs of recurrence. Conclusions We report a case of left parathyroid carcinoma associated with secondary hyperparathyroidism. Concomitant secondary hyperparathyroidism may cause mild hypercalcemia compared to parathyroid carcinoma alone due to the added modification of dialysis. Although our patient also presented with mild hypercalcemia, a D/W ratio > 1 on preoperative echocardiography and presence of recurrent nerve palsy on laryngoscopy led to the suspicion and treatment of parathyroid carcinoma preoperatively.
- Published
- 2023
- Full Text
- View/download PDF
8. Conversion surgery after lenvatinib treatment for anaplastic thyroid carcinoma: a case report
- Author
-
Haruhiko Yamazaki, Katsuhiko Masudo, Sachie Kanada, Yoshiaki Inayama, Hiroyuki Hayashi, Yu Fujii, and Yasushi Rino
- Subjects
Anaplastic thyroid carcinoma ,Conversion surgery ,Lenvatinib ,Surgery ,RD1-811 - Abstract
Abstract Background Anaplastic thyroid carcinoma (ATC) is the most aggressive form of thyroid carcinoma. Lenvatinib, a multikinase inhibitor, is rarely used in preoperative settings due to adverse effects including delayed wound healing and fistula formation. Herein, we report the use of lenvatinib treatment prior to conversion surgery for the treatment of ATC. Case presentation A 71-year-old woman was referred to our hospital with suspected thyroid cancer with recurrent laryngeal nerve invasion and cervical lymph node metastasis based on the results of ultrasonography. Computed tomography demonstrated the presence of a thyroid tumor invading the trachea and esophagus with no evidence of distant metastasis. Fine needle aspiration of the left cervical lymph node indicated the lymph node metastasis of ATC. As the tumor had widely invaded the trachea and esophagus, unresectable ATC was diagnosed and treatment with lenvatinib was initiated at a dose of 24 mg/day. On day 13 of lenvatinib treatment, the primary tumor and lymph node metastases demonstrated a partial response to therapy. As the tumor was now considered resectable, the decision was made to perform conversion surgery. Total thyroidectomy and left lateral neck node dissection were performed 7 days after the withdrawal of lenvatinib. The patient was discharged on postoperative day 5 with no complications. Histopathological examination demonstrated that the tumor contained the component of papillary thyroid carcinoma, squamoid ATC cells, and granulation tissue. In areas of granulation tissue, atypical cells with spindle-shaped or polygonal morphology, pyknotic nuclei, and scant cytoplasm were observed. Immunohistochemically, these cells were positive for cytokeratin AE1/AE3, TTF-1, and p53 and negative for thyroglobulin and PAX8. Therefore, the areas of granulation tissue observed within tumor samples were also considered ATC that were affected by lenvatinib treatment. In total, approximately 50% of resected tumor comprised ATC, and 70% of them had been changed to granulation tissue. Conclusions The findings in the present case indicate that lenvatinib may have significant antitumor effects in preoperative settings. Lenvatinib may represent a promising candidate therapy for unresectable ATC by increasing tumor resectability.
- Published
- 2023
- Full Text
- View/download PDF
9. Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma
- Author
-
Haruhiko Yamazaki, Kiminori Sugino, Ryohei Katoh, Kenichi Matsuzu, Chie Masaki, Junko Akaishi, Kiyomi Yamada Hames, Chisato Tomoda, Akifumi Suzuki, Keiko Ohkuwa, Wataru Kitagawa, Mitsuji Nagahama, Yasushi Rino, and Koichi Ito
- Subjects
anaplastic thyroid carcinoma ,neoadjuvant chemotherapy ,paclitaxel ,prognosis ,response ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract The clinical utilities of paclitaxel in anaplastic thyroid carcinoma (ATC) have been reported. The current study investigated the outcomes in ATC patients treated by paclitaxel as neoadjuvant setting. Furthermore, the prognostic factor for overall survival (OS) and predictive marker for response to paclitaxel were investigated. Records of ATC patients treated by paclitaxel as neoadjuvant setting in our hospital were reviewed. The median OS for the patients with (n = 43) and without (n = 23) resection were 14.7 (95% CI, 11.0–21.7) and 4.2 (95% CI, 3.0–5.4) months, respectively (p
- Published
- 2023
- Full Text
- View/download PDF
10. Parathyroid carcinoma with pancreatitis causing hypercalcaemic emergency treated with extracorporeal membrane oxygenation-assisted parathyroid resection
- Author
-
Madoka Toyoda, Nobuyasu Suganuma, Akari Takahashi, Taku Masuda, Masami Goda, Tatsuya Yoshida, Norio Yukawa, Shoji Yamanaka, Yasushi Rino, and Munetaka Masuda
- Subjects
Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Emergencies due to malignancies usually have a severe clinical course and require urgent treatment. These scenarios are dubbed ‘oncologic emergencies’. Parathyroid tumours often cause hypercalcaemia but not oncologic emergencies. We present a case of parathyroid carcinoma with severe hypercalcaemia and pancreatitis, resolved by surgical resection of the tumour assisted by extracorporeal membrane oxygenation (ECMO). A 66-year-old woman presented to our hospital because of haematuria. Laboratory findings were as follows: white blood cell count: 30 000, C-reactive protein: 17.7, calcium: 21.9, creatine kinase: 316, creatine kinase-myoglobin binding: 20, troponin I: 1415.8, amylase: 1046, lipase: 499, blood urea nitrogen: 57, and creatinine: 2.42. ECG was unremarkable. CT revealed a 4-cm low-density irregular tumour in the left lobe of the thyroid gland and severe pancreatitis. We diagnosed hypercalcaemia and pancreatitis due to parathyroid carcinoma. Volume expansion with isotonic saline was started immediately. Calcitonin, followed by denosumab, calcimimetic agents, and continuous hemodiafiltration were administered. The patient’s general condition worsened due to uncontrolled hypercalcaemia. Urgent tumour resection was planned, assisted with ECMO for cardiopulmonary support and surgical field venous pressure reduction. Tumour histology was suggestive of parathyroid carcinoma. Hypercalcaemia and the patient’s general condition improved gradually postoperatively. Hypercalcaemia is one of the oncologic emergency symptoms, commonly occurring because of lytic bone metastasis. However, reports about parathyroid carcinoma-causing life-threatening hypercalcaemia and pancreatitis are scarce; the fatality of this condition is estimated to be 30–70%. We report a case of survival of hypercalcaemia of malignancy.
- Published
- 2023
- Full Text
- View/download PDF
11. Solitary Cardiac Metastasis from Colorectal Cancer: A Case Report
- Author
-
Koji Numata, Nozomi Urata, Yuta Nakayama, Mihwa Ju, Ayano Tanaka, Hirotaka Nakayama, Kazuki Yamanaka, Shinsuke Hatori, Osamu Matsubara, Yasushi Rino, and Kazuyuki Tani
- Subjects
colorectal cancer ,cardiac metastasis ,resection ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
A 73-year-old woman with silent cardiac metastasis underwent high anterior resection for rectal cancer 3 years ago. Follow-up computed tomography showed a tumor in the right atrium. Partial vascular resection of the superior vena cava and right atrium was performed. Early postoperative recurrence occurred, and chemotherapy was unsuccessful. The patient died 7 months after surgery.
- Published
- 2022
- Full Text
- View/download PDF
12. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status
- Author
-
Tetsuya Isaka, Hiroyuki Ito, Tomoyuki Yokose, Haruhiro Saito, Hiroyuki Adachi, Kotaro Murakami, Jun Miura, Noritake Kikunishi, and Yasushi Rino
- Subjects
EGFR mutation ,Pathological stage ,Relapse-free survival ,Primary lung adenocarcinoma ,Adjuvant chemotherapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Pathological stage IB-IIIA lung adenocarcinoma with an epidermal growth factor receptor (EGFR) mutation (Mt) has a high recurrence rate even after complete resection. However, there have been few reports on the risk factors for Mt recurrence. This study aimed to analyze the clinicopathological factors related to the relapse-free survival (RFS) of patients with pathological stage IB-IIIA primary lung adenocarcinoma with and without an EGFR mutation. Methods Patients who underwent curative surgery for Mt (n = 208) harboring the EGFR exon 21 L858R point mutation or EGFR exon 19 deletion mutation and EGFR mutation wild-type lung adenocarcinoma (Wt, n = 358) between January 2010 and December 2020 were included. Patients who received adjuvant EGFR-tyrosine kinase inhibitors were excluded. The prognostic factors for RFS were analyzed using a multivariable Cox regression analysis. Results The 5-year RFS rates in the Mt and Wt groups were 43.5 and 52.3%, respectively (p = 0.907). Prognostic factors for RFS in the Mt group included smoking history (hazard ratio [HR], 1.49; p = 0.049), blood vessel invasion (HR, 1.84; p = 0.023), and lymph node metastasis (HR, 1.96; p = 0.005). However, adjuvant chemotherapy was not a prognostic factor (HR, 1.02; p = 0.906). In contrast, positron emission tomography (PET) max standardized uptake value (SUV) ≥ 6.0 (HR, 1.53; p = 0.042), lymphatic vessel invasion (HR, 1.54; p = 0.036), lymph node metastasis (HR, 1.79; p = 0.002), and adjuvant chemotherapy (HR, 0.60; p = 0.008) were prognostic factors for RFS in the Wt group. Conclusions Prognostic factors for RFS in stage IB-IIIA primary lung adenocarcinoma differ by epidermal growth factor receptor mutation status. The impact of adjuvant chemotherapy on RFS also differed by EGFR mutation status.
- Published
- 2022
- Full Text
- View/download PDF
13. Gastric cancer biomarker analysis in patients treated with different adjuvant chemotherapy regimens within SAMIT, a phase III randomized controlled trial
- Author
-
Takashi Oshima, Akira Tsuburaya, Kazuhiro Yoshida, Takaki Yoshikawa, Yohei Miyagi, Yasushi Rino, Munetaka Masuda, Jia Guan, Patrick Tan, Heike I. Grabsch, Junichi Sakamoto, and Shiro Tanaka
- Subjects
Medicine ,Science - Abstract
Abstract Biomarkers for selecting gastric cancer (GC) patients likely to benefit from sequential paclitaxel treatment followed by fluorinated-pyrimidine-based adjuvant chemotherapy (sequential paclitaxel) were investigated using tissue samples of patients recruited into SAMIT, a phase III randomized controlled trial. Total RNA was extracted from 556 GC resection samples. The expression of 105 genes was quantified using real-time PCR. Genes predicting the benefit of sequential paclitaxel on overall survival, disease-free survival, and cumulative incidence of relapse were identified based on the ranking of p-values associated with the interaction between the biomarker and sequential paclitaxel or monotherapy groups. Low VSNL1 and CD44 expression predicted the benefit of sequential paclitaxel treatment for all three endpoints. Patients with combined low expression of both genes benefitted most from sequential paclitaxel therapy (hazard ratio = 0.48 [95% confidence interval, 0.30–0.78]; p
- Published
- 2022
- Full Text
- View/download PDF
14. The Clinical Impact of the Pretreatment Albumin to Fibrinogen Ratio in Esophageal Cancer Patients Who Receive Curative Treatment.
- Author
-
TORU AOYAMA, YUKIO MAEZAWA, ITARU HASHIMOTO, KENTARO HARA, KEISUKE KAZAMA, KEISUKE KOMORI, AYA KATO, KAZUKI OTANI, AYAKO TAMAGAWA, HARUHIKO CHO, JUNYA MORITA, SHINNOSUKE KAWAHARA, MIE TANABE, TAKASHI OSHIMA, AYA SAITO, NORIO YUKAWA, and YASUSHI RINO
- Subjects
ALBUMINS ,FIBRINOGEN ,TREATMENT of esophageal cancer ,CANCER relapse ,CLINICAL trials - Abstract
Background/Aim: The albumin to fibrinogen ratio (AFR) has been identified as a promising prognostic marker for some malignancies. The aim of the present study was to evaluate the clinical impact of AFR in esophageal cancer patients who received curative resection. Patients and Methods: The present study included 123 patients who underwent curative treatment for esophageal cancer between 2005 and 2020. The prognosis and clinicopathological parameters were compared between patients with high and low AFRs. Results: The overall survival (OS) stratified by each clinical factor was compared using the log-rank test, and a significant difference was observed when using a pretreatment AFR of 1.23. When comparing the patient backgrounds between the high-AFR (AFR ≥12.3) and low- AFR (AFR<12.3) groups, significant differences were noted in the pathological T status. The high-AFR group had significantly higher OS rates at 3 years (70.8%) and 5 years (59.3%) after surgery in comparison to the low-AFR group (46.6% and 37.4%, respectively). Univariate and multivariate analyses for OS showed that the AFR was a significant prognostic factor. In addition, when comparing the site of first recurrence, a marginally significant difference was noted in hematological recurrence. Conclusion: The AFR is a significant risk factor in patients with esophageal cancer, holding promise as a valuable prognostic factor. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Clinicopathological Characteristics and Prognosis of Mucinous Gastric Cancer
- Author
-
KEISUKE KOMORI, KAZUKI KANO, SHUJI ANDO, HAYATO WATANABE, KOSUKE TAKAHASHI, YUKIO MAEZAWA, HIROHITO FUJIKAWA, SHO SAWAZAKI, MASAKATSU NUMATA, TORU AOYAMA, TAKANOBU YAMADA, HIROSHI TAMAGAWA, NORIO YUKAWA, YASUSHI RINO, TAKASHI OGATA, and TAKASHI OSHIMA
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2023
16. Clinical Significance of Pre-treatment Circumferential Tumor Location in Patients With cStage IB-III Esophageal Squamous Cell Cancer
- Author
-
SHINSUKE NAGASAWA, TAKASHI OSHIMA, KENTARO HARA, MASATO NAKAZONO, YUTA KUMAZU, TORU AOYAMA, TAKANOBU YAMADA, TAKASHI OGATA, YASUSHI RINO, AYA SAITO, TOMOYUKI YOKOSE, and HEIKE I. GRABSCH
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2023
17. A case of aortic dissection after placing a thoracic endovascular stent to perform left lung surgery
- Author
-
Hiroyasu Koga, Takuya Nagashima, Tetsukan Woo, Haruhiko Masuda, Shoichiro Ono, and Yasushi Rino
- Subjects
General Medicine - Published
- 2023
18. The clinical impacts of the prognostic nutritional index for the esophageal cancer patients who received curative treatment.
- Author
-
Toru Aoyama, Yosuke Atsumi, Shinnosuke Kawahara, Hiroshi Tamagawa, Ayako Tamagawa, Yukio Maezawa, Kazuki Kano, Masaaki Murakawa, Keisuke Kazama, Masakatsu Numata, Takashi Oshima, Norio Yukawa, Munetaka Masuda, and Yasushi Rino
- Subjects
ADJUVANT treatment of cancer ,ESOPHAGEAL cancer ,CANCER relapse ,DISEASE risk factors ,PERIOPERATIVE care - Abstract
Background: We investigated the impact of the prognostic nutritional index (PNI) on esophageal cancer survival and recurrence after curative treatment. Methods: This study included 120 patients who underwent curative surgery followed by the adjuvant treatment for esophageal cancer between 2008 and 2018. The risk factors for overall survival (OS) and recurrence-free survival (RFS) were identified. Results: The PNI of 49 was regarded to be the optimal critical point of classification considering the 1-year, 3-year, and 5-year survival rate. The OS rates at three and five years after surgery were 47.4% and 36.0% in the PNI low group, respectively, and 62.5% and 56.5% in the PNI high group, which amounted to a statistically significant difference (P = 0.020). The RFS rates at three and five years after surgery were 31.0% and 24.8% in the PNI low group, respectively, and 50.9% and 42.8% in the PNI high group, which amounted to a statistically significant difference (P = 0.020). A multivariate analysis demonstrated that the PNI was a significant independent risk factor for the OS and a marginally significant independent risk factor forRFS. Conclusion: The PNI was a risk factor for survival in patients who underwent curative treatment for esophageal cancer. It is necessary to develop the effective plan of the perioperative care and the surgical strategy according to the PNI. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Clinical Impact of the C-reactive Protein-albumin-lymphocyte Index in Post-gastrectomy Patients With Gastric Cancer.
- Author
-
ITARU HASHIMOTO, MIE TANABE, SHIZUNE ONUMA, JYUNYA MORITA, SHINSUKE NAGASAWA, YUKIO MAEZAWA, KYOHEI KANEMATSU, TORU AOYAMA, TAKANOBU YAMADA, NORIO YUKAWA, TAKASHI OGATA, YASUSHI RINO, AYA SAITO, and TAKASHI OSHIMA
- Subjects
STOMACH cancer treatment ,GASTRECTOMY ,ALBUMINS ,LYMPHOCYTES ,C-reactive protein - Abstract
Background/Aim: Recently, preoperative inflammatory, immune, and nutritional statuses have attracted attention as prognostic factors in post-curative gastrectomy patients with gastric cancer (GC). The usefulness of the Creactive protein-albumin-lymphocyte (CALLY) index as a prognostic factor in patients with various cancers, has been reported. However, reports on the clinical significance of the CALLY index in patients with GC after gastrectomy remain inadequate. In this prospective study, we focused on the preoperative CALLY index and investigated its usefulness as a prognostic factor in patients with GC. Patients and Methods: This study included 459 patients who underwent gastrectomy for GC between December 2013 and November 2017 at Kanagawa Cancer Center, Kanagawa, Japan. The preoperative CALLY index was calculated based on the preoperative blood test data. Patients were divided into high- and low-CALLY groups. The associations of the preoperative CALLY scores with clinicopathological factors, overall survival (OS), and recurrence-free survival (RFS) after gastrectomy for GC were evaluated. Results: The low-CALLY group was significantly older, had higher venous invasion, and a more progressive pStage than did the high-CALLY group. OS and RFS after gastrectomy in the low-CALLY group were significantly worse than those in the high-CALLY group (77.9% vs. 88.9%; p<0.001 and 73.8% vs. 87.1%; p<0.001, respectively). In the multivariate analysis, a low CALLY score was an independent prognostic factor of worse OS and RFS. Conclusion: Preoperative CALLY levels may be a useful prognostic predictor in patients with GC after curative gastrectomy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. The Clinical Benefit of the Modified Neutrophil-Platelet Score as a Surrogate Prognostic Marker in Patients With Resectable Gastric Cancer.
- Author
-
KAZUKI OTANI, TORU AOYAMA, YUKIO MAEZAWA, ITARU HASHIMOTO, NATSUMI KAMIYA, AYA KATO, MASAKATSU NUMATA, SHINNOSUKE KAWAHARA, AYAKO TAMAGAWA, MASATO NAKAZONO, HIROSHI TAMAGAWA, KENKI SEGAMI, KEISUKE KAZAMA, SHO SAWAZAKI, NORIO YUKAWA, AYA SAITO, and YASUSHI RINO
- Subjects
STOMACH cancer treatment ,NEUTROPHILS ,CANCER prognosis ,GASTRECTOMY ,BLOOD platelets - Abstract
Background/Aim: Gastric cancer is a common cause of cancer death worldwide, especially in East Asia. This study evaluated the impact of preoperative modified Neutrophil-Platelet Score (mNPS) on the survival and recurrence of patients with resectable gastric cancer. Patients and Methods: The study analyzed 168 patients who underwent curative gastrectomy and subsequently received adjuvant treatment for gastric cancer between 2015 and 2021. Univariate and multivariate analyses were performed to identify the risk factors for overall survival (OS) and recurrence-free survival (RFS). Results: Patients were divided into two groups: 76 patients with an mNPS of 0 were classified into the low-mNPS group, whereas 92 patients with an mNPS of =1 were classified into the high-mNPS group. The 3- and 5-year OS rates in the low-mNPS group were 65.6% and 56.2%, respectively, and those in the high-mNPS group were 45.3% and 36.9%, respectively. The difference in OS between the two groups was statistically significant (p=0.007). The 3- and 5-year RFS rates in the low-mNPS group were 45.6% and 38.7%, respectively, whereas those in the highmNPS group were 33.4% and 28.1%, respectively. The difference in RFS between the two groups was statistically significant (p=0.043). A multivariate analysis showed that the mNPS was a significant independent prognostic factor for OS and RFS. Conclusion: mNPS is a potential prognostic marker for patients with gastric cancer who underwent curative gastrectomy. Higher mNPS values were associated with lower 3- and 5-year OS and RFS rates, indicating a potential correlation between elevated mNPS and worse outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Survival Predictors Before Preoperative Adjuvant Chemotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma.
- Author
-
ITARU HASHIMOTO, KAZUKI KANO, HIDEAKI SUEMATSU, TAKANOBU YAMADA, HAYATO WATANABE, KYOHEI KANEMATSU, SHINSUKE NAGASAWA, TORU AOYAMA, TAKASHI OGATA, YASUSHI RINO, AYA SAITO, and TAKASHI OSHIMA
- Subjects
TREATMENT of esophageal cancer ,ADJUVANT chemotherapy ,SQUAMOUS cell carcinoma ,PREOPERATIVE care ,C-reactive protein - Abstract
Background/Aim: Radical resection after preoperative adjuvant chemotherapy (NAC) is a standard treatment for patients with locally advanced esophageal squamous cell carcinoma (LAESCC), but its outcome remains unsatisfactory. In order to develop a personalized treatment program for LAES, we herein compared the survival prediction utility of five pre-NAC nutritional, inflammatory, and immune indexes in patients with LAESCC. Patients and Methods: We evaluated the survival of 203 patients with LAESCC who underwent radical resection after NAC from January 2011 to September 2019 for the following representative pre-NAC nutritional, inflammatory, and immune indices: modified Glasgow Prognostic Score, Prognostic Nutritional Index, C-reactive protein/albumin ratio, serum neutrophil/lymphocyte ratio, and Geriatric Nutrition Risk Index (GNRI) were evaluated for their impact on survival. Results: Of the five indices, GNRI was the best predictor of survival as determined by the area under the curve (p<0.05). When patients were divided into three groups according to the nutritional risk assessment of Bouillanne et al. using the pre-NAC GNRI, the 5-year overall survival (OS) and recurrence-free survival (RFS) were significantly stratified (p<0.001). On multivariate analysis, the GNRI independently identified a poor OS group [group 1: hazard ratio (HR)=2.598, p=0.002; group 2: HR=6.257, p<0.001] and a high recurrence risk group (group 1: HR=1.967, p=0.016; group 2: HR=4.467, p<0.001). Conclusion: In patients with LAESCC, GNRI may be the most accurate, reliable, and useful prognostic factor among the five major systemic inflammatory and nutritional indices. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Clinical Significance of Cancer Stem Cell Markers in Primary and Metastatic Tissues in Patients With Breast Cancer
- Author
-
TAKASHI YAMANAKA, TAKASHI OSHIMA, DAISUKE MURAYAMA, SAKI OKAMOTO, AI MATSUI, MIO YASUKAWA, YUKA MATSUBARA, SOJI TODA, YUKIHIKO HIROSHIMA, TORU AOYAMA, NOBUYASU SUGANUMA, YASUSHI RINO, AYA SAITO, YOHEI MIYAGI, HIROYUKI IWASAKI, and TOSHINARI YAMASHITA
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2023
23. Tumor DNA in Peritoneal Lavage as a Novel Biomarker for Predicting Peritoneal Recurrence in Patients With Gastric Cancer
- Author
-
NORIO YUKAWA, TAKESHI YAMADA, TORU AOYAMA, TEKKAN WOO, KOJI UEDA, AKIHISA MASTUDA, KENTARO HARA, KEISUKE KAZAMA, HIROSHI TAMAGAWA, TSUTOMU SATO, TAKASHI OSHIMA, AKIHIRO SUZUKI, HIROYUKI ABURATANI, SHUMPEI ISHIKAWA, AYA SAITO, MUNETAKA MASUDA, HIROSHI YOSHIDA, and YASUSHI RINO
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2023
24. Incidence and Risk of Venous Thromboembolism in Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy
- Author
-
MARIKO KAMIYA, SHINNOSUKE KAWAHARA, YUTO KAMIOKA, MASAAKI MURAKAWA, TORU AOYAMA, SATOSHI KOBAYASHI, MAKOTO UENO, NAOTO YAMAMOTO, TAKASHI OSHIMA, NORIO YUKAWA, YASUSHI RINO, MUNETAKA MASUDA, and SOICHIRO MORINAGA
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2023
25. Clinical Significance of Neutrophil-to-Lymphocyte Ratio/Serum Albumin Ratio in Patients With Metastatic Gastric or Gastroesophageal Junction Cancer Administered Trifluridine/Tipiracil
- Author
-
ITARU HASHIMOTO, KAZUKI KANO, SHIZUNE ONUMA, HIDEAKI SUEMATSU, SHINSUKE NAGASAWA, KYOHEI KANEMATSU, KYOKO FURUSAWA, TOMOMI HAMAGUCHI, MAMORU WATANABE, KEI HAYASHI, MITSUHIRO FURUTA, YASUHIRO INOKUCHI, NOZOMU MACHIDA, TORU AOYAMA, TAKANOBU YAMADA, YASUSHI RINO, TAKASHI OGATA, and TAKASHI OSHIMA
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2023
26. Multiancestry genomic and transcriptomic analysis of gastric cancer
- Author
-
Yasushi Totoki, Mihoko Saito-Adachi, Yuichi Shiraishi, Daisuke Komura, Hiromi Nakamura, Akihiro Suzuki, Kenji Tatsuno, Hirofumi Rokutan, Natsuko Hama, Shogo Yamamoto, Hanako Ono, Yasuhito Arai, Fumie Hosoda, Hiroto Katoh, Kenichi Chiba, Naoko Iida, Genta Nagae, Hiroki Ueda, Chen Shihang, Shigeki Sekine, Hiroyuki Abe, Sachiyo Nomura, Tetsuya Matsuura, Eiji Sakai, Takashi Ohshima, Yasushi Rino, Khay Guan Yeoh, Jimmy So, Kaushal Sanghvi, Richie Soong, Akihiko Fukagawa, Shinichi Yachida, Mamoru Kato, Yasuyuki Seto, Tetsuo Ushiku, Atsushi Nakajima, Hitoshi Katai, Patrick Tan, Shumpei Ishikawa, Hiroyuki Aburatani, and Tatsuhiro Shibata
- Subjects
Genetics - Published
- 2023
27. Validation of EZH2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines
- Author
-
HIROTAKA NAKAYAMA, NAO SAITO, RIKA KASAJIMA, NOBUYASU SUGANUMA, YASUSHI RINO, KATSUHIKO MASUDO, HARUHIKO YAMAZAKI, SOJI TODA, KAZUMASA SEKIHARA, HIROYUKI IWASAKI, and DAISUKE HOSHINO
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2023
28. A multicenter investigation of risk factors for recurrence in elderly patients with stage II colorectal cancer
- Author
-
Akio Higuchi, Toru Aoyama, Yosuke Atsumi, Keisuke Kazama, Sho Sawazaki, Masakatsu Numata, Hiroshi Tamagawa, Teni Godai, Hitoshi Murakami, Norio Yukawa, Hiroyuki Saeki, and Yasushi Rino
- Subjects
Cancer Research ,Oncology ,Pharmacology (medical) - Published
- 2023
29. Clinical Course of Vitamin B12 Deficiency and Associated Risk Factors in Patients After Total Gastrectomy for Gastric Cancer
- Author
-
TORU AOYAMA, KENTARO HARA, YUKIO MAEZAWA, KEISUKE KAZAMA, ITARU HASHIMOTO, SHO SAWAZAKI, KEISUKE KOMORI, HIROSHI TAMAGAWA, AYAKO TAMAGAWA, KAZUKI KANO, HARUHIKO CHO, JUNYA MORITA, KENKI SEGAMI, MIE ISHIMOTO, TAKASHI OSHIMA, NORIO YUKAWA, and YASUSHI RINO
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2023
30. Should the splenic hilar lymph node be dissected for the management of adenocarcinoma of the esophagogastric junction?
- Author
-
Yuta Kumazu, Shinichi Hasegawa, Tsutomu Hayashi, Takanobu Yamada, Hayato Watanabe, Kentaro Hara, Yota Shimoda, Masato Nakazono, Shinsuke Nagasawa, Yasushi Rino, Munetaka Masuda, Takashi Ogata, Takashi Oshima, and Takaki Yoshikawa
- Subjects
Oncology ,Surgery ,General Medicine - Abstract
Splenic hilar lymphadenectomy is not recommended for advanced proximal gastric cancer that does not invade the greater curvature according to the results of the previous studies. The efficacy of splenic hilar lymphadenectomy for type II and type III adenocarcinomas of the esophagogastric junction and easy spread to the greater curvature of the stomach remains unclear. This study aimed to investigate the efficacy of splenic hilar lymphadenectomy and identify the risk factors for metastasis to splenic hilar nodes.We examined patients who underwent R0/1 gastrectomy for Siewert types II and III at a single high-volume center in Japan. We analyzed the metastatic incidence, therapeutic value index, and risk factors for splenic hilar lymph node metastasis.We examined 126 patients (74, type II; 52, type III). Splenectomy was performed in 76 patients. Metastatic incidence and the therapeutic value index of splenic hilar lymph nodes in patients with type II and type III tumors were 4.5% and 0, and 21.9% and 9.4, respectively. In the patients who underwent splenectomy, we identified Siewert type III tumors (odds ratio: 6.93, 95% confidence interval: 1.24-38.8, p = 0.027) and tumor location other than the lesser curvature (odds ratio: 7.36, 95% confidence interval: 1.32-41.1, p = 0.023) to be independent risk factors. The metastatic incidence (46.2%) and therapeutic value index (15.4) were high in patients with both risk factors.Splenic hilar lymphadenectomy may contribute to the survival of patients with Siewert type III tumors, especially when the predominant location is not the lesser curvature.
- Published
- 2023
31. Clinical Significance ofSEC11AExpression in Patients With Locally Advanced Gastric Cancer
- Author
-
HIDEAKI SUEMATSU, KENTARO SAKAMAKI, NAOHIDE OUE, YUKIHIKO HIROSHIMA, YAYOI KIMURA, SHIZUNE ONUMA, ITARU HASHIMOTO, SHINSUKE NAGASAWA, TORU AOYAMA, TAKANOBU YAMADA, HIROSHI TAMAGAWA, TAKASHI OGATA, YASUSHI RINO, MUNETAKA MASUDA, WATARU YASUI, YOHEI MIYAGI, and TAKASHI OSHIMA
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2022
32. Prognostic Value of the Perioperative Systemic Inflammation Score for Patients With Curatively Resected Gastric Cancer
- Author
-
Mihwa, Ju, Toru, Aoyama, Momoko, Fukuda, Tetsushi, Ishiguro, Kazuki, Kano, Keisuke, Kazama, Sho, Sawazaki, Hiroshi, Tamagawa, Norio, Yukawa, and Yasushi, Rino
- Subjects
Research Article - Abstract
Background/Aim: The systemic inflammation score (SIS) is a promising tool for the evaluation of prognosis. The present study aimed to evaluate the clinical impact of the preoperative SIS status in gastric cancer (GC) patients who underwent curative resection. Patients and Methods: This study retrospectively analyzed 258 patients with primary gastric cancer who received curative treatment at Yokohama City University. The SIS was evaluated before surgery as determined by the lymphocyte-to-monocyte ratio (cut-off value=4.44) and serum albumin level (cut-off value=4.0 g/dl). Results: A high SIS was identified as an independent predictor of overall survival [hazard ratio (HR)=1.784, p
- Published
- 2022
33. The Clinical Impact of Other Primary Cancer in Patients Who Received Curative Treatment for Esophageal Cancer
- Author
-
Toru, Aoyama, Yukio, Maezawa, Kentaro, Hara, Miwha, Ju, Keisuke, Komori, Hiroshi, Tamagawa, Ayako, Tamagawa, Keisuke, Kazama, Sho, Sawazaki, Itaru, Hashimoto, Kazuki, Kano, Haruhiko, Cho, Junya, Morita, Kenki, Segami, Tetsushi, Ishiguro, Tsutomu, Sato, Takashi, Oshima, Norio, Yukawa, and Yasushi, Rino
- Subjects
Neoplasms, Multiple Primary ,Survival Rate ,Cancer Research ,Esophageal Neoplasms ,Oncology ,Humans ,Neoplasms, Second Primary ,General Medicine ,Prognosis ,Retrospective Studies - Abstract
The present study evaluated the clinical impact of other metachronous or synchronous primary cancer (OPC) in patients who received curative treatment for esophageal cancer.The present study included 168 patients who underwent curative treatment for esophageal cancer between 2005 and 2018. Prognosis and differences between the OPC status (metachronous/synchronous) and clinic pathological parameters was analyzed.A total of 168 patients were included in this study. Forty patients were diagnosed with metachronous/synchronous OPC. When comparing the clinicopathological factors between the patients with and without OPC, the patients' background and postoperative clinical courses were very similar between the two groups. The 3- and 5-year overall survival rates in patients with esophageal cancer with OPC were 66.0% and 54.5%, respectively, while those in patients without OPC were 50.1% and 41.4%, respectively. There was no statistically significant difference in these rates (p=0.156). The OPC status was not included in the final multivariate analysis model.The OPC status was not found to be a prognostic factor for patients who received curative treatment for esophageal cancer. Therefore, it is not necessary to avoid performing curative treatment for esophageal cancer because of a patient's OPC status.
- Published
- 2022
34. Impact of Local Control on Clinical Course in Stage IVC Anaplastic Thyroid Carcinoma
- Author
-
Haruhiko Yamazaki, Kiminori Sugino, Ryohei Katoh, Katsuhiko Masudo, Kenichi Matsuzu, Wataru Kitagawa, Mitsuji Nagahama, Yasushi Rino, and Koichi Ito
- Subjects
Survival Rate ,Airway Obstruction ,Thyroidectomy ,Humans ,Surgery ,Thyroid Neoplasms ,Thyroid Carcinoma, Anaplastic ,Prognosis ,Retrospective Studies - Abstract
The present study investigated the association between local resection and cause of death in anaplastic thyroid carcinoma (ATC) patients with stage IVC disease.A total of 54 ATC patients with stage IVC disease were included in the study. Information including patient characteristics, laboratory data including complete blood count, treatment, and death were collected for analysis.The median overall survival (OS) for patients with or without resection was 8.4 [95% confidence interval (CI) 5.9-14.4)] and 4.2 (95% CI 2.5-6.2) months, respectively (p 0.001). No patients survived without resection at 1 year. Univariate analysis revealed that resection (p 0.001) and radiotherapy (p = 0.018) were significantly associated with OS. Multivariate analysis revealed that resection (hazard ratio 0.257; 95% CI 0.115-0.575; p 0.001) was the only independent prognostic factor of OS. In ATC patients with known resection status, the median OS for the patients with a resection status of R0/1 (n = 28) and R2 (n = 7) were 13.0 (95% CI 7.5-18.7) and 1.7 (95% CI 0.1-6.2) months, respectively (p 0.001). The most common specific cause of death was respiratory insufficiency (35%), followed by airway obstruction (25%) and cerebral cardiovascular-related death (5%). The frequency of airway obstruction was significantly lower in patients with resection (p = 0.018).Resection probably impacts on clinical course in ATC patients despite the presence of distant metastasis. However, R2 resection is likely to be harmful and surgeons should carefully consider the resectability of thyroid tumors.
- Published
- 2022
35. Prognostic significance of lung metastasis-related finding in lenvatinib treatment for differentiated thyroid cancer
- Author
-
Haruhiko Yamazaki, Hiroyuki Iwasaki, Katsuhiko Masudo, Soji Toda, Ai Matsui, and Yasushi Rino
- Subjects
Iodine Radioisotopes ,Lung Neoplasms ,Endocrinology ,Phenylurea Compounds ,Endocrinology, Diabetes and Metabolism ,Quinolines ,Humans ,Antineoplastic Agents ,Thyroid Neoplasms ,Adenocarcinoma ,Prognosis - Abstract
Purpose This study aimed to analyze the clinical course of patients with differentiated thyroid cancer (DTC) who were treated by lenvatinib and investigate the specific criteria for the initiation of lenvatinib treatment in lung metastasis.MethodsA total of 111 patients with DTC treated by lenvatinib were included in the study. Patients were divided into two groups based on the target lesion for the initiation of lenvatinib treatment: lung metastasis group and other metastases group.ResultsIn the univariate analysis, the tumor size for the target lesion (p = 0.002) and target lesion (p < 0.001) were significantly associated with overall survival (OS). Multivariate analysis revealed that the target lesion [hazard ratio, 0.408; 95% confidence interval (CI), 0.206–0.810; p = 0.010] was the only independent prognostic factor of OS. Of the 53 patients in the lung metastasis group, 12 (23%) had lung metastasis-related finding such as pleural effusion (n = 12), hemoptysis (n = 2), and dyspnea (n = 1) at the initiation of lenvatinib treatment. The median OS in patients with or without lung metastasis-related findings were 41.0 [95% CI, 10.4–not available (NA)] months and 62.9 (95% CI, 53.0–NA) months, respectively (p = 0.022).ConclusionPatients with lung metastasis-related finding at the initiation of lenvatinib treatment had a poorer prognosis among the lung metastasis group. It is important to consider not only the tumor size but also the presence of lung metastasis-related findings when initiating lenvatinib treatment for DTC patients with lung metastasis.
- Published
- 2022
36. Clinical Impact of Surgical Sarcopenia on Long-term Survival
- Author
-
Keisuke, Komori, Kazuki, Kano, Toru, Aoyama, Kentaro, Hara, Shinsuke, Nagasawa, Masato, Nakazono, Yota, Shimoda, Yukio, Maezawa, Yuta, Kumazu, Taiichi, Kawabe, Masakatsu, Numata, Tsutomu, Hayashi, Takanobu, Yamada, Hiroshi, Tamagawa, Tsutomu, Sato, Haruhiko, Cho, Norio, Yukawa, Yasushi, Rino, Takaki, Yoshikawa, Takashi, Ogata, and Takashi, Oshima
- Subjects
Sarcopenia ,Cancer Research ,Postoperative Complications ,Oncology ,Gastrectomy ,Risk Factors ,Stomach Neoplasms ,Humans ,General Medicine ,Neoplasm Recurrence, Local ,Muscle, Skeletal ,Prognosis ,Retrospective Studies - Abstract
Preoperative sarcopenia is associated with various cancers and affects the long-term prognosis of patients. After gastrectomy for gastric cancer, dynamic changes in body composition occur, and sarcopenia becomes more apparent after surgery than before surgery. However, the relationship between sarcopenia in the early postoperative period and long-term survival is not fully understood. The aim of this study was to determine the effects of surgical sarcopenia on long-term outcomes of patents with gastric cancer.We included 408 patients who underwent curative gastrectomy (distal or total gastrectomy) for gastric cancer at the Kanagawa Cancer Center from December 2013 to November 2017. Sarcopenia was defined using the skeletal muscle index (SMI), using computed tomography (CT) one month after gastrectomy. We compared the long-term outcomes between patients with and without sarcopenia.The 5-year overall survival (OS) rates were 83.2% and 91.4% in the surgical and non-surgical sarcopenia groups, respectively. The hazard ratio (HR) of surgical sarcopenia for OS was 2.410 (95% confidence interval (CI)=1.321-4.396). In addition, surgical sarcopenia was associated with non-cancer-related deaths and deaths from other cancers.Patients with surgical sarcopenia after gastrectomy should be carefully monitored not only for gastric cancer recurrence but also for the occurrence of other diseases, including other cancers.
- Published
- 2022
37. Effect of Preoperative Gastric Shape on Loss of Lean Body Mass After Distal Gastrectomy.
- Author
-
SHINSUKE NAGASAWA, MIE TANABE, SHIZUNE ONUMA, JUNYA MORITA, ITARU HASHIMOTO, HIDEAKI SUEMATSU, TORU AOYAMA, TAKANOBU YAMADA, TAKASHI OGATA, NORIO YUKAWA, YASUSHI RINO, AYA SAITO, and TAKASHI OSHIMA
- Subjects
LEAN body mass ,GASTRECTOMY ,STOMACH cancer ,ADJUVANT chemotherapy ,DISEASE incidence - Abstract
Background/Aim: Based on gastric shape, patients with gastric cancer can be divided into storage (hook-shaped and ptotic stomach) and reverse outflow (steerhorn and cascade stomach) groups. In patients with gastric cancer, postoperative loss of lean body mass (LBM) is associated with a poor prognosis. This study investigated the influence of preoperative gastric shape on LBM loss 1 month after curative distal gastrectomy. Patients and Methods: Between May 2011 and May 2019, we enrolled 487 patients with pathological stage IA/IB/IIA gastric cancer who underwent curative distal gastrectomy and did not receive adjuvant chemotherapy. Patients were divided into storage (n=370) and outflow (n=117) groups according to whether barium was stored in the stomach during the preoperative fluoroscopic examination. Clinicopathological features, LBM 1 month after gastrectomy, and predictors of postoperative LBM loss were compared between the groups using multivariable logistic regression. Results: The incidence of >5% LBM loss and >7.5% body weight loss 1 month postoperatively were significantly higher in the storage group than in the outflow group (p=0.003 and p=0.009, respectively). Multivariable analysis revealed that gastric shape [odds ratio (OR)=3.30, 95% confidence interval (CI)=1.95-5.59, p<0.001], male sex (OR=3.20, 95% CI=2.07-4.96, p<0.001), and Roux-en-Y reconstruction (OR=1.69, 95% CI=1.08-2.64, p=0.02) were independent predictors of LBM loss. Postoperative dietary problems, especially dumping syndrome, diarrhea, and reflux were more common in the storage group (p<0.001). Conclusion: Gastric shape may be a useful independent predictor of postoperative LBM loss in patients with gastric cancer undergoing distal gastrectomy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Clinical Significance of Prealbumin Level Measurement Before Neoadjuvant Chemotherapy in Elderly Patients With Locally Advanced Esophageal Cancer.
- Author
-
HIDEAKI SUEMATSU, TAKANOBU YAMADA, SHIZUNE ONUMA, ITARU HASHIMOTO, KYOHEI KANEMATSU, SHINSUKE NAGASAWA, TORU AOYAMA, TAKASHI OGATA, YASUSHI RINO, AYA SAITO, and TAKASHI OSHIMA
- Subjects
NEOADJUVANT chemotherapy ,ESOPHAGEAL cancer ,TRANSTHYRETIN ,ESOPHAGECTOMY ,OLDER patients - Abstract
Background/Aim: Radical esophagectomy after preoperative neoadjuvant chemotherapy (NAC) is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC). However, careful treatment selection is required when considering organ function in elderly patients. Prealbumin, a rapid turnover protein, is a short-term dynamic nutritional index, and its relationship with long-term postoperative survival in various cancers has been previously reported. However, the association between serum prealbumin level before NAC and survival in elderly patients remains unclear. This study investigated the clinical significance of prealbumin level measurement before NAC in elderly patients with locally advanced ESCC who underwent surgery after NAC. Patients and Methods: Eighty patients aged =65 years diagnosed with cStage II/III ESCC and undergoing radical esophagectomy after cisplatin and 5-fluorouracil therapy as NAC, were included. The cutoff value of the serum prealbumin level before NAC was set at 18.2 mg/dl using receiver operating characteristic curve analysis, and postoperative complications, recurrence, and overall survival were compared between the low and high prealbumin groups. Results: There were no differences in patient background, clinicopathological characteristics, postoperative complications, or recurrence-free survival between the two groups. Overall survival (OS) was significantly worse in the low prealbumin group than in the high prealbumin group (5-year survival, 33.3% vs. 67.0%; p=0.0341). Furthermore, on univariate and multivariate analysis, low prealbumin level was an independent poor OS factor (p=0.036). Conclusion: In elderly patients with locally advanced ESCC, serum prealbumin level before NAC may be a useful prognostic factor and may be important in selecting a treatment strategy that considers individual organ function. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Significance of Preoperative Modified Nutritional Risk Index in Patients With Gastric Cancer After Curative Resection.
- Author
-
HAYATO WATANABE, ITARU HASHIMOTO, MIE TANABE, SHIZUNE ONUMA, JUNYA MORITA, SHINSUKE NAGASAWA, KYOHEI KANEMATSU, TORU AOYAMA, TAKANOBU YAMADA, TAKASHI OGATA, YASUSHI RINO, AYA SAITO, and TAKASHI OSHIMA
- Subjects
STOMACH cancer ,SURGICAL excision ,SERUM albumin ,BODY mass index ,SURGICAL complications - Abstract
Background/Aim: A new modified nutritional risk index (mNRI), calculated using serum albumin (g/l)+body mass index (BMI) [weight (kg_/height² (m²)], is a good predictor of postoperative complications and cancer survival. However, no study has used this index in patients with gastric cancer (GC). Therefore, we aimed to investigate the clinical significance of the preoperative mNRI values in patients with GC who underwent curative resection. Patients and Methods: We examined 449 patients who underwent curative resection for GC at Kanagawa Cancer Center between 2013 and 2017. The mNRI cutoff value obtained using a receiver operating characteristic analysis was 23.31. Patients were divided into high and low mNRI groups according to the cutoff value, and the clinicopathological characteristics and outcomes were compared between the two groups. Results: In terms of clinicopathological characteristics, the high mNRI group had a higher proportion of men, higher BMI, and a higher proportion of patients with American Society of Anesthesiologists physical status class 2/3 compared with the low mNRI group; the low mNRI group had significantly worse 5-year recurrence-free survival (RFS) and overall survival (OS) than the high mNRI group (OS, p=0.005) (OS, p=0.006; RFS, p=0.018) did. In the multivariate analysis, a low mNRI was an independent predictor of OS (p=0.006) and RFS (p=0.013). Conclusion: Preoperative mNRI may be a useful recurrence and prognostic biomarker in patients with GC who have undergone curative resection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Clinical Significance of EREG Gene Expression in Gastric Cancer Tissue After Curative Surgery
- Author
-
HIDEAKI SUEMATSU, ITARU HASHIMOTO, YUKIHIKO HIROSHIMA, HAYATO WATANABE, KAZUKI KANO, KOSUKE TAKAHASHI, TORU AOYAMA, TAKANOBU YAMADA, HIROSHI TAMAGAWA, TAKASHI OGATA, NORIO YUKAWA, YASUSHI RINO, MUNETAKA MASUDA, YOHEI MIYAGI, and TAKASHI OSHIMA
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2022
41. PD-L1 expression in anaplastic thyroid carcinoma treated with lenvatinib
- Author
-
Haruhiko Yamazaki, Yoichiro Okubo, Tomoyuki Yokose, Hiroyuki Iwasaki, Tetsuro Sasada, Katsuhiko Masudo, Soji Toda, Ai Matsui, Mei Kadoya, Yasushi Rino, and Yohei Miyagi
- Abstract
Purpose This study aimed to estimate the proportion of patients with anaplastic thyroid carcinoma (ATC) at our institution who are likely to have the efficacy of immune checkpoint inhibitor (ICI) treatment by investigating programmed cell death ligand 1 (PD-L1) expression. Additionally, we investigated the association between PD-L1 expression and treatment outcomes of lenvatinib in patients with ATC. Methods The 19 lenvatinib-treated patients with ATC whose tissue samples available for immunohistochemistry were included in this study. The tumor proportion score (TPS) ≥1%was determined as positive for PD-L1 expression Results Of the 19 patients, 5 (26%) and 14 (74%) had a partial response to lenvatinib treatment and PD-L1 expression positivity, respectively. The median TPS was 30% in patients with positive PD-L1 expression. The median OS for all 19 patients was 4.8 (95% confidence interval [CI], 2.8–6.6) months with a 6-month OS rate of 36.8%. Furthermore, the median OS for patients with positive or negative PD-L1 expression was 5.3 (95% CI, 1.6–7.8) and 4.2 (95% CI, 1.1–not available) months, respectively (p = 0.277). Conclusion No correlation was observed between the PD-L1 expression in the ATC tissue samples and efficacy of lenvatinib. Furthermore, in our study, 14 (74%) of 19 patients with ATC had PD-L1 expression positivity. Although lenvatinib monotherapy may have limited efficacy, some patients with ATC have the possibility that the addition of ICI on lenvatinib is effective.
- Published
- 2023
42. Migration of Risk Classification Between the JAES Versus ATA guidelines for Papillary Thyroid Carcinoma
- Author
-
Haruhiko Yamazaki, Katsuhiko Masudo, and Yasushi Rino
- Subjects
Surgery - Published
- 2023
43. The Systemic Inflammation Score Is an Independent Prognostic Factor for Esophageal Cancer Patients who Receive Curative Treatment
- Author
-
Toru, Aoyama, Mihwa, Ju, Keisuke, Komori, Hiroshi, Tamagawa, Ayako, Tamagawa, Yukio, Maezawa, Itaru, Hashimoto, Kazuki, Kano, Kentaro, Hara, Haruhiko, Cho, Kenki, Segami, Daisuke, Machida, Masato, Nakazono, Takashi, Oshima, Norio, Yukawa, and Yasushi, Rino
- Subjects
Inflammation ,Survival Rate ,Cancer Research ,Esophageal Neoplasms ,Oncology ,Humans ,General Medicine ,Prognosis - Abstract
Perioperative systemic inflammation affects the long-term oncological outcomes in cases of malignancies. We evaluated the clinical impact of the preoperative systemic inflammation score (SIS) in resectable esophageal cancer patients who received curative treatment.This study included 168 patients who underwent curative surgery followed by perioperative adjuvant chemotherapy for esophageal cancer between 2005 and 2018. The risk factors for overall survival (OS) and recurrence-free survival (RFS) were identified.Based on the 3- and 5-year OS rate, we set the cut-off value for SIS at 2 in the preset study. Among the 168 total patients, 119 were categorized as the Low-SIS group, and 49 were categorized as the High-SIS group. The respective 3- and 5-year OS rates were 61.9% and 52.4% in the Low-SIS group and 33.3% and 26.6% in the High-SIS group. There were significant differences in OS (p0.001). The SIS was therefore selected for the final multivariate analysis model (hazard ratio=2.094, 95% confidence interval=1.355-3.234, p0.001). On comparing the perioperative clinical course between the High- and Low-SIS groups, there were significant differences in the rate of postoperative anastomosis leakage of grade ≥2 between the groups (61.5% in the High-SIS group vs. 30.3% in the Low-SIS group; p=0.021).The systemic inflammation score had a clinical effect on the long-term oncological outcomes in esophageal cancer patients, suggesting that it might be a promising prognostic factor for esophageal cancer patients.
- Published
- 2022
44. Impact of Infectious Complications on Survival and Recurrence of Patients With Stage II/III Colorectal Cancer: A Multicenter Retrospective Study
- Author
-
Hiroshi, Tamagawa, Toru, Aoyama, Masakatsu, Numata, Keisuke, Kazama, Yosuke, Atsumi, Kenta, Iguchi, Mihwa, Ju, Sho, Sawazaki, Sumito, Sato, Kazuki, Kano, Takashi, Ohshima, Takanobu, Yamada, Teni, Godai, Akio, Higuchi, Hiroyuki, Saeki, Norio, Yukawa, and Yasushi, Rino
- Subjects
Survival Rate ,Cancer Research ,Postoperative Complications ,Oncology ,Humans ,Anastomotic Leak ,General Medicine ,Colorectal Neoplasms ,Retrospective Studies - Abstract
Postoperative complications are associated with increased recurrence in colorectal cancer (CRC). We investigated the impact of infectious complications on the recurrence of CRC and overall survival after curative surgery in a single study group.In total, 1,668 patients who underwent radical resection for CRC in Yokohama City University, Yokohama Minami Kyosai Hospital, and Kanagawa Cancer Center between 2011 and 2019 were reviewed. Patients were classified into those with infectious complications (IC group) and those without infectious complications (Non-IC group). The risk factors for recurrence-free survival (RFS) and overall survival (OS) were analyzed.Postoperative complications were found in 560 of the 1,668 patients (33.5%), and IC, which occurred in 312 patients (18.7%), included pneumonia, anastomotic leakage, and intraperitoneal abscess. The 5-year OS rates in the Non-IC and IC groups were 95.5% and 90.4%, respectively, while the 5-year RFS rates were 74.4% and 68.1%, respectively. The multivariate analysis demonstrated that postoperative IC were significant independent risk factors for OS and RFS.The presence of postoperative IC after CRC resection is associated with decreased long-term survival. The surgical procedure, surgical strategy, and perioperative care should be carefully planned in order to avoid causing IC.
- Published
- 2022
45. Chemotherapy-induced Reversion of Mutant RAS to Wild-type RAS in Metastatic Colorectal Cancer
- Author
-
SUMITO SATO, YO MIKAYAMA, MANABU SHIOZAWA, SUGURU NUKADA, KENTA IGUCHI, HIRONAO OKAMOTO, TAKASHI KOHMURA, KEISUKE KAZAMA, KUNIYA TANAKA, TAKASHI OSHIMA, and YASUSHI RINO
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2022
46. Laparoscopic extended right hemicolectomy versus laparoscopic transverse colectomy for mid-transverse colon cancer: a multicenter retrospective study from Kanagawa Yokohama Colorectal Cancer (KYCC) study group
- Author
-
Kenta Iguchi, Masakatsu Numata, Manabu Shiozawa, Keisuke Kazama, Sho Sawazaki, Yusuke Katayama, Koji Numata, Sumito Sato, Akio Higuchi, Nobuhiro Sugano, Hiroyuki Mushiake, and Yasushi Rino
- Subjects
Treatment Outcome ,Colonic Neoplasms ,Gastroenterology ,Humans ,Laparoscopy ,Colectomy ,Colon, Transverse ,Retrospective Studies - Abstract
The laparoscopic surgery approach for mid-transverse colon cancer (MTC) varies depending on tumor characteristics and the guidelines implemented by each surgeon; the optimal surgical procedure for MTC has not been established. This study aimed to compare the surgical outcomes of laparoscopic extended right hemicolectomy (Lap-ERHC) and laparoscopic transverse colectomy (Lap-TC) for MTC.This was a multicenter, retrospective study. We surveyed eight hospitals, by questionnaire, on MTC surgery policies and retrospectively compared the short- and long-term surgical outcomes for patients with MTC who underwent Lap-ERHC or Lap-TC between January 2008 and December 2019.A total of 129 patients were enrolled, of whom 35 underwent Lap-ERHC and 94 underwent Lap-TC. There were no significant differences in tumor progression between the two groups. Operation time was significantly longer (202 min vs. 185 min, p = 0.026). We observed a higher complication rate (≥ grade 3) in the Lap-ERHC group than in the Lap-TC group (11.4% vs. 3.2%, p = 0.086). Three patients (8.6%) who underwent Lap-ERHC developed anastomotic leakage; none of the patients who underwent Lap-TC had this complication (p = 0.018). The 3-year overall survival rates (stage I: 100% vs. 91.9%, p = 0.64; stage II: 100% vs. 95.5%, p = 0.46; stage III: 100% vs. 88.2%, p = 0.91, respectively) were similar between the two groups.Lap-ERHC for MTC has the same long-term outcomes as Lap-TC. However, Lap-ERHC for MTC has a higher complication rate. Therefore, Lap-TC may be recommended for patients with MTC.UMIN000042674.
- Published
- 2022
47. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial
- Author
-
Jia Guan, Takaki Yoshikawa, Shiro Tanaka, Heike I. Grabsch, Yohei Miyagi, Yasushi Rino, Jeeyun Lee, Junichi Sakamoto, Nesaretnam Barr Kumarakulasinghe, Yiong Huak Chan, Takashi Oshima, Michal Marek Hoppe, Anand D. Jeyasekharan, Mark De Simone, Munetaka Masuda, Akira Tsuburaya, Kazuhiro Yoshida, Cedric Chuan Young Ng, Raghav Sundar, Angie Lay-Keng Tan, Patrick Tan, RS: GROW - R2 - Basic and Translational Cancer Biology, and Pathologie
- Subjects
Oncology ,medicine.medical_specialty ,Paclitaxel ,medicine.medical_treatment ,adjuvant treatment ,Adenocarcinoma ,THERAPY ,Disease-Free Survival ,Ramucirumab ,Machine Learning ,chemistry.chemical_compound ,CISPLATIN ,Stomach Neoplasms ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Stomach cancer ,UFT ,DOCETAXEL ,Chemotherapy ,business.industry ,gastric cancer ,Gastroenterology ,Cancer ,Gene signature ,CHEMOTHERAPY ,medicine.disease ,COMPREHENSIVE MOLECULAR CHARACTERIZATION ,TUMORS ,FAMILY ,Clinical trial ,chemistry ,Cohort ,5-FLUOROURACIL ,SENSITIVITY ,business - Abstract
ObjectiveTo date, there are no predictive biomarkers to guide selection of patients with gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional group Trial (SAMIT) was a 2×2 factorial randomised phase III study in which patients with GC were randomised to Pac-S-1 (paclitaxel +S-1), Pac-UFT (paclitaxel +UFT), S-1 alone or UFT alone after curative surgery.DesignThe primary objective of this study was to identify a gene signature that predicts survival benefit from paclitaxel chemotherapy in GC patients. SAMIT GC samples were profiled using a customised 476 gene NanoString panel. A random forest machine-learning model was applied on the NanoString profiles to develop a gene signature. An independent cohort of metastatic patients with GC treated with paclitaxel and ramucirumab (Pac-Ram) served as an external validation cohort.ResultsFrom the SAMIT trial 499 samples were analysed in this study. From the Pac-S-1 training cohort, the random forest model generated a 19-gene signature assigning patients to two groups: Pac-Sensitive and Pac-Resistant. In the Pac-UFT validation cohort, Pac-Sensitive patients exhibited a significant improvement in disease free survival (DFS): 3-year DFS 66% vs 40% (HR 0.44, p=0.0029). There was no survival difference between Pac-Sensitive and Pac-Resistant in the UFT or S-1 alone arms, test of interaction pConclusionUsing machine-learning techniques on one of the largest GC trials (SAMIT), we identify a gene signature representing the first predictive biomarker for paclitaxel benefit.Trial registration numberUMIN Clinical Trials Registry: C000000082 (SAMIT); ClinicalTrials.gov identifier, 02628951 (South Korean trial)
- Published
- 2022
48. Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab
- Author
-
Hideaki, Suematsu, Kazuki, Kano, Takanobu, Yamada, Itaru, Hashimoto, Hayato, Watanabe, Kosuke, Takahashi, Mamoru, Watanabe, Kei, Hayashi, Yoshihiro, Kaneta, Mitsuhiro, Furuta, Yasuhiro, Inokuchi, Nozomu, Machida, Toru, Aoyama, Hiroshi, Tamagawa, Norio, Yukawa, Yasushi, Rino, Munetaka, Masuda, Takashi, Ogata, and Takashi, Oshima
- Subjects
Adult ,Aged, 80 and over ,Male ,Cancer Research ,Time Factors ,General Medicine ,Middle Aged ,Progression-Free Survival ,Nivolumab ,Oncology ,Stomach Neoplasms ,Humans ,Female ,Neoplasm Metastasis ,Immune Checkpoint Inhibitors ,Aged ,Retrospective Studies - Abstract
To evaluate the impact of development of nivolumab monotherapy-induced immune-related adverse events (irAEs) and continuing nivolumab with irAEs on the survival of patients with gastric cancer (GC).Patients with unresectable advanced GC and recurrence after curative resection who received nivolumab monotherapy were included in the study. Survival was compared between patients who did and did not develop irAEs, and between those who continued and discontinued treatment due to irAEs.Of 110 GC patients, 22 developed irAEs. Grade ≥3 IrAEs included rash and diarrhoea associated with enteritis. Progression-free and overall survival (OS) were significantly better in patients with irAEs than in those without. The overall survival of patients who continued treatment despite irAEs was better than that of those who discontinued treatment.irAE development was associated with better survival in patients with GC who received nivolumab monotherapy. Continuing nivolumab with appropriate treatment in GC patients with irAEs may improve survival.
- Published
- 2022
49. Postoperative acute pancreatitis after pancreatic resection in patients with pancreatic ductal adenocarcinoma
- Author
-
Masaaki Murakawa, Yuto Kamioka, Shinnosuke Kawahara, Naoto Yamamoto, Satoshi Kobayashi, Makoto Ueno, Manabu Morimoto, Hiroshi Tamagawa, Takashi Ohshima, Norio Yukawa, Yasushi Rino, Munetaka Masuda, and Soichiro Morinaga
- Subjects
Pancreatic Neoplasms ,Pancreatic Fistula ,Pancreatectomy ,Postoperative Complications ,Pancreatitis ,Risk Factors ,Acute Disease ,Humans ,Surgery ,Carcinoma, Pancreatic Ductal ,Pancreaticoduodenectomy ,Retrospective Studies - Abstract
Postoperative pancreatic fistula (POPF) is one of the major critical complications after pancreatic resection. Recently, postoperative acute pancreatitis (POAP), a new concept for a pancreatic-specific complication following pancreatic resection, has been advocated, and its association with POPF has been reported. The present study examined the clinical features of POAP and identified the associations of POAP with POPF and other postoperative morbidities in pancreatic ductal adenocarcinoma (PDAC) patients undergoing pancreatic resection.A total of 312 consecutive patients who underwent pancreatic resection for PDAC at our institution from 2013 to 2019 were enrolled in this study. POAP was defined as an elevated serum amylase level above the upper limit normal on postoperative day (POD) 0 or 1, based on Connor's definition. The severity of POPF was assessed by the International Study Group on Pancreatic Surgery definition.A total of 184 patients (58.9%) had POAP. POAP occurred in 58.5% of subtotal stomach-preserving pancreatoduodenectomy patients and 60% of distal pancreatectomy combined with splenectomy patients. The presence of POAP was significantly associated with the development of clinically relevant POPF, higher rates of severe morbidity, and a prolonged hospital stay after pancreatic resection. A multivariate analysis showed that the presence of POAP and elevated C-reactive protein levels on POD 3 were independent predictors of clinically relevant POPF after subtotal stomach-preserving pancreatoduodenectomy.POAP is associated with the development of POPF, higher rates of severe morbidity, and a prolonged hospital stay after pancreatic resection and is an independent risk factor for clinically relevant POPF after pancreatoduodenectomy. POAP represents an important indicator for planning treatment strategies to prevent serious complications, including POPF.
- Published
- 2022
50. The Comparison of the Dietary Intake Loss Between Elderly and Non-Elderly Patients After Gastrectomy for Gastric Cancer
- Author
-
Masato, Nakazono, Toru, Aoyama, Keisuke, Komori, Hayato, Watanabe, Kazuki, Kano, Shinsuke, Nagasawa, Kenki, Segami, Hiroshi, Tamagawa, Norio, Yukawa, Yasushi, Rino, Takashi, Ogata, and Takashi, Oshima
- Subjects
Oncology ,Gastroenterology - Abstract
Background/Aim The present study quantified the changes in the dietary and nutritional intake after gastrectomy between elderly and non-elderly patients. Patients and Methods This prospective observational study enrolled patients who underwent curative gastrectomy for gastric cancer. Results Twenty-three patients ≥ 75 years old were classified into the elderly group, and 127 patients p = 0.075 and 0.080). On comparing the intake loss of three major nutrients, the respective median % lipid intake losses at 1 and 3 months postoperatively were −13.5% and −5.8% in the elderly group and −7.3% and 0% in the non-elderly group (p = 0.029 and 0.045). Conclusion Our results suggested that elderly patients experienced more serious lipid intake loss after gastrectomy than non-elderly patients.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.